The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers…
Inês Martins, PhD
Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Inês Martins, PhD
Transplanting 3D bioprinted liver tissue into diseased livers improves liver health in mice, Organovo Holdings revealed. The finding suggests that…
CHOLESTASIS
NewsAlbireo Plans Phase 3 Trial of A4250 to Treat Children with Life-threatening Liver Disease
Children with progressive familial intrahepatic cholestasis will be able to take part in a Phase 3 clinical trial of A4250’s ability…
FATTY LIVER DISEASE
NewsEarly Study to Test Bioelectronic Treatment for NASH Inflammation
A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning,…
Novartis is exercising an option to become the exclusive developer and global marketer of Conatus Pharmaceuticals‘ liver-disease treatment emricasan.
GENFIT has enrolled the first patient in a Phase 2a clinical trial of elafibranor as a treatment for a liver bile…
Can-Fite BioPharma has concluded preparations for its Phase 2 trial evaluating namodenoson (CF102) for the treatment of non-alcoholic fatty liver…
Patients with advanced, inoperable hepatocellular carcinoma (HCC) may highly benefit from Immunitor‘s new oral immunotherapeutic vaccine, Hepko-V5 (hepcortespenlisimut-L), according to results…
The U.S. Food and Drug Administration has granted orphan drug status to cabozantinib for the treatment of hepatocellular carcinoma, the most…
Consuming fructose, a sweetener used in processed foods and sodas, is an established risk factor for obesity and related metabolic…